Abstract 164P
Background
5-Fluorouracil (5-FU) is a key drug in treatment of unresectable advanced gastric cancer (AGC). It is known that intravenous 5-FU and oral fluorouracil have different mechanism as anti-cancer drugs, however, a clinical benefit of intravenous 5-FU after using oral fluorouracil is not clear. Therefore, we planned a prospective study to assess the efficacy and safety of weekly intravenous 5-FU and l-leucovorin(l-LV) in Japanese patients with AGC which was resistant for oral fluorouracil, taxane, and platinum. This encore abstract was previously reported at the ESMO 21st World Congress on Gastrointestinal Cancer 2019; the abstract number was P-176.
Methods
This regimen consisted of l-LV 250mg/m2/2h iv and 5-FU 600mg/m2 iv once a week for 6 weeks followed by 2-week rest period, within an 8-week cycle. The primary endpoint was the progression free survival (PFS) rate at 8 weeks.
Results
Among the 29 enrolled patients, PFS rate at 8 weeks was 55.2% (95% CI 35.6% to 71.0%), which was higher than 47.5% which is the expected value of the hypothesis, and the lower limit of 95% CI is significantly higher than the threshold which is 23.1%. Grade 3 to 4 hematological adverse events (AE) were as follows; anemia 20.7%, neutropenia 3.4%, and platelet count decreased 3.4%. Grade 3 to 4 non-hematological AE were observed as follows; anorexia 20.7%, fatigue 13.8%, and diarrhea 3.4%.
Conclusions
The intravenous 5-FU and l-LV regimen is feasible and could be promising as the salvage line treatment in patients with AGC even if that is resistant for oral fluorouracil, taxane and platinum.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Helsinki Ethical Principles (revised in Oct, 2013) and the Ethical Guidelines for Medical and Health Research involving in Human Subjects in 2014.
Funding
Hokkaido Gastrointestinal Cancer Study Group.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract